Background Specific antibodies, including antibodies to cyclic citrullinated peptide (ACCP) and modified citrullinated vimentin (AMCV) are markers of severe course of rheumatoid arthritis (RA). At the same time, rheumatoid arthritis often associated with autoimmune thyroiditis (Hashimoto's thyroiditis (HT)).
Objectives Evaluate the role of antibodies to ACCP and AMCV on the clinical and laboratory features of rheumatoid arthritis in association with autoimmune thyroiditis.
Methods The study included two groups of patients. The first group of patients included 16 patients (14 men and 2 women, mean age - 62.37±2.12 years) with RA in combination with HT and detection in the blood only ACCP (group 1). The second group also included 16 patients (14 women and 2 men, mean age – 52.31±4.94 years) with RA in combination with HT and detection of ACCP and AMCV in the blood (group 2). In the first group of patients 10 patients had euthyreose, from 5 - hypothyroidism, compensated intake of L - thyroxine, 1 patient - thyrotoxicosis underway medikal euthyreose. In the second group of patients was observed in 14 patients euthyreose, from 2 - hypothyroidism, compensated reception L-thyroxine.
Results Both groups of patients differed on the following parameters studied: erosion detected in 68% in group 1 and 50% in group 2 (p<0,05), in the first group of patients predominated (62%) the high degree of activity of RA by DAS-28, in while in group 2 - the average (56%, p<0,05).
By using correlation analysis Spearman correlation relationships among the studied attracted attention significant (R =0,62, p<0,05) relationship between erosions and detection in the blood of antibodies to ACCP in the second group of patients (a combination of RA and HT and identifying in blood ACCP and AMCV), which was repeatedly weakened and unreliable in group 1 (combination of RA and HT and only detect of ACCP) in the blood.
Conclusions Second group patients (a combination of RA with HT and detection in blood ACCP and AMCV) are closer correlations with indicators of joint destruction than group 1 patients, that in the future may use as a prognostic marker of a more severe course of RA in combination with HT.
Disclosure of Interest None declared